{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Decreased+Immunologic+Activity",
    "query": {
      "condition": "Decreased Immunologic Activity"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 386,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Decreased+Immunologic+Activity&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:43:57.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00072969",
      "title": "A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 132,
      "start_date": "2003-11",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072969"
    },
    {
      "nct_id": "NCT02178683",
      "title": "Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Tacrolimus and MMF.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Colorado Blood Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2010-11",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2014-07-01",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178683"
    },
    {
      "nct_id": "NCT00135694",
      "title": "Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C",
        "Hepatitis C, Chronic",
        "Nonimmune Nonviral Causes of Liver Failure"
      ],
      "interventions": [
        {
          "name": "calcineurin inhibitor-based immunosuppression",
          "type": "DRUG"
        },
        {
          "name": "liver transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "immunosuppression withdrawal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2005-10",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135694"
    },
    {
      "nct_id": "NCT01909245",
      "title": "Islet Cell Transplant for Type 1 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Allogenic Human Islet Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunosuppressive Agents",
          "type": "DRUG"
        },
        {
          "name": "Gastrin 17",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 10,
      "start_date": "2013-10-16",
      "completion_date": "2026-09-22",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01909245"
    },
    {
      "nct_id": "NCT01853618",
      "title": "Tremelimumab With Chemoembolization or Ablation for Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heptocellular Cancer",
        "Biliary Tract Neoplasms",
        "Liver Cancer",
        "Hepatocellular Carcinoma",
        "Biliary Cancer"
      ],
      "interventions": [
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "RFA",
          "type": "PROCEDURE"
        },
        {
          "name": "TACE",
          "type": "PROCEDURE"
        },
        {
          "name": "Cryoablation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 61,
      "start_date": "2013-05-02",
      "completion_date": "2017-06-07",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853618"
    },
    {
      "nct_id": "NCT00492869",
      "title": "Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "AEB071",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2007-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492869"
    },
    {
      "nct_id": "NCT00010335",
      "title": "Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Systemic Lupus Erythematosus",
        "Dermatomyositis",
        "Juvenile Rheumatoid Arthritis",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "CD34 selection",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 6,
      "start_date": "2000-11",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00010335"
    },
    {
      "nct_id": "NCT03445234",
      "title": "Blueberries, Bananas, Exercise Recovery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Response",
        "Metabolic Disturbance",
        "Immune Suppression"
      ],
      "interventions": [
        {
          "name": "Blueberry",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "banana",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "No banana",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Appalachian State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-09-11",
      "completion_date": "2017-12-15",
      "has_results": false,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 1,
      "location_summary": "Kannapolis, North Carolina",
      "locations": [
        {
          "city": "Kannapolis",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03445234"
    },
    {
      "nct_id": "NCT00001034",
      "title": "The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections",
        "Gastrointestinal Diseases"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 850,
      "start_date": null,
      "completion_date": "1995-08",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001034"
    },
    {
      "nct_id": "NCT00895583",
      "title": "Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Graft Rejection",
        "Kidney Transplant",
        "Renal Allograft Recipients",
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2009-06",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-05-22T04:43:57.343Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895583"
    }
  ]
}